The expression of CCL3 and CCL4 is increased in chronic lymphocytic leukemia, and can be used as biomarkers in the therapy targeting chronic lymphocytic leukemia [67, 68]. Here, CCL4 is linked to B-cell chronic lymphocytic leukemia.